FrancophonIA/ELRC3.0 huggingface dataset:
English: Raltegravir granules for oral suspension should be used during pregnancy only if the expected benefit justifies the potential risk to the foetus.
Slovenian: Raltegravir zrnca za peroralno suspenzijo se lahko med nosečnostjo uporablja samo, če pričakovana korist upravičuje morebitno tveganje za plod.
English: Excipient with known effect Each tablet contains 26.06 mg lactose (as monohydrate).
Slovenian: Pomožna snov z znanim učinkom Ena tableta vsebuje 26,06 mg laktoze (v obliki monohidrata).
English: Raltegravir 400 mg twice daily may be administered with or without food.
Slovenian: Raltegravir v odmerku 400 mg dvakrat na dan se lahko jemlje skupaj s hrano ali brez.
English: In some studies, co-administration of raltegravir 400 mg tablets twice daily with darunavir resulted in a modest but clinically insignificant decrease in darunavir plasma concentrations.
Slovenian: V nekaterih študijah je sočasna uporaba 400 mg tablet raltegravirja dvakrat na dan skupaj z darunavirjem povzročila zmerno, a klinično nepomembno, zmanjšanje koncentracije darunavirja v plazmi.
English: > 50 and ≤ 200 cells/mm
Slovenian: > 50 in ≤ 200 celic/mm
English: For mean CD4 changes, baselinecarry-forward was used for virologic failures.
Slovenian: Pri povprečni spremembi števila celic CD4 je virološki neuspeh opredeljen od izhodišča naprej.
English: Myopathy and rhabdomyolysis have been reported.
Slovenian: Poročali so o pojavu miopatije in rabdomiolize.
English: The use of ISENTRESS is not recommended in pre-term neonates.
Slovenian: Uporaba zdravila ISENTRESS pri nedonošenih novorojenčkih ni priporočljiva.
English: Uncommon immune reconstitution syndrome, drug hypersensitivity, hypersensitivity
Slovenian: Bolezni imunskega sistema občasni sindrom imunske obnove, preobčutljivost na zdravilo, preobčutljivost
English: Food appears to increase pharmacokinetic variability relative to fasting.
Slovenian: Kaže, da se variabilnost farmakokinetičnih lastnosti v prisotnosti hrane v primerjavi s stanjem na tešče poveča.
English: Birth to 1 Week - Once daily dosing
Slovenian: Od rojstva do 1 tedna - Odmerjanje enkrat na dan od 2 do manj kot 3
English: Co-administration of raltegravir with a calcium carbonate antacid decreased raltegravir plasma levels; however, this interaction is not considered clinically meaningful.
Slovenian: Sočasna uporaba raltegravirja z antacidom, ki vsebuje kalcijev karbonat, je zmanjšala plazemsko koncentracijo raltegravirja, vendar se ta interakcija ne smatra kot klinično pomembna.
English: Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.
Slovenian: Bolnikom je treba pojasniti, da morajo v primeru pojava bolečine v sklepih, okorelosti sklepov ali težav pri gibanju poiskati zdravniško pomoč.
English: Raltegravir Pharmacokinetic Parameters IMPAACT P1066 Following Administration of Doses in Section 4.2 (excluding neonates)
Slovenian: Farmakokinetični parametri raltegravirja v študiji IMPAACT P1066 po aplikaciji odmerkov, navedenih v poglavju 4.2 (brez novorojenčkov)
English: • acne; unusual hair loss or thinning; redness of skin; unusual distribution of fat on the body, this may include loss of fat from legs, arms, and face, and increase in abdomen fat; excessive sweating; night sweats; thickening and itching of the skin due to repeated scratching; skin lesion; dry skin
Slovenian: • akne, nenavadno izgubljanje ali tanjšanje las, pordelost kože, nenavadna porazdelitev maščevja na telesu, ki lahko vključuje zmanjšanje maščevja na nogah, rokah in obrazu ter povečanje trebušne maščobe, prekomerno znojenje, nočno znojenje, zadebeljenost in srbenje kože zaradi stalnega praskanja, poškodbe kože, suha koža
English: In drug interaction studies performed using raltegravir 400 mg twice daily, raltegravir did not have a clinically meaningful effect on the pharmacokinetics of etravirine, maraviroc, tenofovir disoproxil fumarate, hormonal contraceptives, methadone, midazolam or boceprevir.
Slovenian: V študijah medsebojnega delovanja, pri uporabi 400 mg raltegravirja dvakrat na dan, raltegravir ni klinično pomembno vplival na farmakokinetiko etravirina, maraviroka, tenofovirdizoproksil fumarata, hormonskih kontraceptivov, metadona, midazolama ali boceprevirja.
English: In addition, relative to the raltegravir 400 mg formulation the raltegravir 600 mg formulation used in the 1,200 mg (2 x 600 mg) once daily dosing regimen has higher relative bioavailability (by 21 to 66%).
Slovenian: Poleg tega ima 600-mg oblika, uporabljena v odmerni shemi 1.200 mg enkrat na dan (2 x 600 mg), v primerjavi s 400-mg obliko večjo relativno biološko uporabnost (za 21 do 66 %).
English: Randomisation was stratified by screening HIV RNA level (≤ 100,000 copies/mL; and > 100,000 copies/mL) and by hepatitis B or C status (positive or negative).
Slovenian: Randomizacija je bila stratificirana glede na vrednost HIV RNA ob presejanju (≤ 100.000 kopij/ml in > 100.000 kopij/ml) in glede na status hepatitisa B ali C (pozitiven ali negativen).
English: Common: the following may affect up to 1 in 10 people
Slovenian: Pogosti: pojavijo se lahko pri največ 1 od 10 bolnikov
English: In addition, tenofovir disoproxil fumarate may increase plasma levels of raltegravir, however, the mechanism for this effect is unknown (see Table 1).
Slovenian: Tudi tenofovirdizoproksil fumarat lahko poveča plazemske koncentracije raltegravirja, vendar pa mehanizem tega učinka ni znan (glejte preglednico 1).
English: Based on these findings, co-administration of aluminium/magnesium and calcium carbonate containing antacids with raltegravir 1,200 mg once daily is not recommended.
Slovenian: Na osnovi teh ugotovitev sočasna uporaba antacidov, ki vsebujejo aluminij/magnezij ali kalcijev karbonat, in 1.200 mg raltegravirja enkrat na dan ni priporočljiva.
English: Injury, poisoning and procedural complications
Slovenian: Poškodbe in zastrupitve ter postopkovni zapleti občasni nenamerno preveliko odmerjanje
English: At Week 240, the treatment difference (raltegravir - efavirenz) was 9.5 % with an associated 95 % CI of (1.7, 17.3).
Slovenian: Razlika v zdravljenju (raltegravir - efavirenz) v 240. tednu je bila 9,5 % pri upoštevanju 95-odstotnega intervala zaupanja (1,7, 17,3).
English: Slowly push in the plunger to give the prepared Isentress.
Slovenian: Bat počasi potiskajte, da boste dali pripravljeno zdravilo Isentress.
English: Table 9: Raltegravir Pharmacokinetic Parameters IMPAACT P1110 Following Age and Weight Based Dosing of the Granules for Suspension
Slovenian: Preglednica 9: Farmakokinetični parametri raltegravirja v študiji IMPAACT P1110 po uporabi zrnc za suspenzijo, v odmerku glede na starost in telesno maso
English: The SWITCHMRK 1 & 2 (Protocols 032 & 033) studies evaluated HIV-infected patients receiving suppressive (screening HIV RNA < 50 copies/mL; stable regimen > 3 months) therapy with lopinavir 200 mg (+) ritonavir 50 mg 2 tablets twice daily plus at least 2 nucleoside reverse transcriptase inhibitors and randomised them 1:1 to continue lopinavir (+) ritonavir 2 tablets twice daily (n=174 and n=178, respectively) or replace lopinavir (+) ritonavir with raltegravir 400 mg twice daily (n=174 and n=176, respectively).
Slovenian: V študijah SWITCHMRK 1 in 2 (protokola 032 & 033) so ovrednotili bolnike, okužene s HIV, ki so bili na supresivni terapiji (HIV RNA < 50 kopij/ml, stabilen režim > 3 mesece), in sicer 2 tableti z 200 mg lopinavirja (+) in 50 mg ritonavirja dvakrat na dan ter vsaj 2 nukleozidna zaviralca reverzne transkriptaze, in ki so jih randomizirali 1:1, tako da so nadaljevali z jemanjem po 2 tableti z lopinovirjem (+) ritonavirjem dvakrat na dan (n = 174 oz. n = 178) ali pa so lopinavir (+) ritonavir zamenjali z raltegravirjem v odmerku 400 mg dvakrat na dan (n = 174 oz. n = 176).
English: 60 chewable tablets
Slovenian: 60 žvečljivih tablet
English: Administration of a low fat meal with raltegravir 1,200 mg once daily resulted in a 42% decrease in AUC0-last, 52% decrease in Cmax, and 16% decrease in C24hr.
Slovenian: Uporaba 1.200 mg raltegravirja enkrat na dan po obroku z majhno vsebnostjo maščob je povzročila zmanjšanje AUC0-last za 42 %, zmanjšanje Cmax za 52 % in zmanjšanje C24ur za 16 %.
English: Pull the plungers out of any syringes you used.
Slovenian: Bate potegnite iz uporabljenih brizg.
English: In addition, tenofovir disoproxil fumarate may increase plasma levels of raltegravir, however, the mechanism for this effect is unknown (see Table 3).
Slovenian: Tudi tenofovirdizoproksil fumarat lahko poveča plazemske koncentracije raltegravirja, vendar pa mehanizem tega učinka ni znan (glejte preglednico 3).
English: Two components, namely raltegravir and raltegravir-glucuronide, were detected in urine and accounted for approximately 9 and 23 % of the dose, respectively.
Slovenian: V urinu so odkrili dve komponenti: raltegravir in raltegravirjev glukuronid, in sicer je raltegravir predstavljal približno 9 % odmerka, raltegravirjev glukuronid pa 23 % odmerka.
English: Yellow, oval-shaped, dimensions 19.1 mm x 9.7 mm x 6.1 mm, marked with MSD corporate logo and “242” on one side and plain on the other side.
Slovenian: filmsko obložena tableta rumena, ovalna, 19,1 mm x 9,7 mm x 6,1 mm velika tableta, z logotipom podjetja MSD in oznako "242" na eni strani in brez oznak na drugi strani
English: Therefore, co administration of emtricitabine/tenofovir disaproxil fumarate and raltegravir 1,200 mg once daily ispermitted.
Slovenian: Zato je sočasna uporaba kombinacije emtricitabin/tenofovirdizoproksil fumarat in 1.200 mg raltegravirja enkrat na dan dovoljena.
English: For analysis by prognostic factors, virologic failures were carried forward for percent < 40 copies/mL.
Slovenian: Pri analizi po prognostičnih faktorjih je virološki neuspeh prenesen naprej za odstotek < 40 kopij/ml.
English: The types and rates of specific cancers were those expected in a highly immunodeficient population.
Slovenian: Specifična rakava obolenja so po vrsti in deležu ustrezala pričakovanim pri bolnikih z močno imunsko pomanjkljivostjo.
English: Excipients with known effect 25 mg
Slovenian: Pomožne snovi z znanim učinkom - 25 mg:
English: 2 green (3 mL) syringes
Slovenian: 2 zeleni (3-ml) brizgi
English: Adults The recommended dosage is 400 mg (one tablet) twice daily.
Slovenian: Odrasli Priporočeni odmerek je 400 mg (ena tableta) dvakrat na dan.
English: • increased liver blood tests; abnormal white blood cells; increased fat levels in blood; increased level of enzyme from salivary glands or pancreas
Slovenian: • zvišane vrednosti krvnih jetrnih testov, nenormalne bele krvne celice, zvišana koncentracija maščob v krvi, zvišane vrednosti encimov iz žlez slinavk ali trebušne slinavke
English: Raltegravir 600 mg (1,200 mg once daily)
Slovenian: raltegravir 600 mg (1.200 mg enkrat na dan)
English: Two pack sizes are available: 1 bottle with 60 tablets, and a multipack containing 180 (3 bottles of 60) tablets.
Slovenian: Na voljo sta dve velikosti pakiranja: 1 plastenka s 60 tabletami in multi pakiranje, ki vsebuje 180 (3 plastenke po 60) tablet.
English: Based on in vitro and in vivo studies, raltegravir is eliminated mainly by metabolism via a UGT1A1-mediated glucuronidation pathway.
Slovenian: Na osnovi in vitro ter in vivo študij se raltegravir v glavnem izloča s presnavljanjem z glukuronidacijo z UGT1A1.
English: • lymph node pain; low count of white blood cells that fight infection; swollen glands in the neck, armpit and groin
Slovenian: • bolečina v bezgavkah, nizko število belih krvnih celic, ki se borijo proti okužbi, otekle bezgavke na vratu, pod pazduho in v dimljah
English: Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation: however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.
Slovenian: Poročajo, da se med imunsko reaktivacijo lahko pojavijo tudi avtoimunske bolezni (kot sta Gravesova bolezen in avtoimunski hepatitis); čas do njihovega nastanka je spremenljiv, zato se lahko pojavijo tudi več mesecev po začetku zdravljenja.
English: Agents that increase gastric pH
Slovenian: Zdravila, ki zvišajo pH v želodcu
English: Patients with rare hereditary problems of fructose intolerance glucosegalactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Slovenian: Bolniki z redko dedno intoleranco za fruktozo, malabsorpcijo glukoze/galaktoze ali pomanjkanjem saharoza-izomaltaze ne smejo jemati tega zdravila.
English: Following administration of an oral dose of radiolabeled raltegravir, approximately 51 and 32 % of the dose was excreted in faeces and urine, respectively.
Slovenian: Po peroralni uporabi z radioaktivnim izotopom označenega raltegravirja se je približno 51 % odmerka izločilo z blatom, približno 32 % odmerka pa z urinom.
English: In faeces, only raltegravir was present, most of which is likely to be derived from hydrolysis of raltegravir-glucuronide secreted in bile as observed in preclinical species.
Slovenian: V blatu je bil prisoten le raltegravir, ki je v največji meri verjetno nastal pri hidrolizi raltegravirjevega glukuronida in se izločil z žolčem, kar so opazili v predkliničnih raziskavah.
English: Geometric mean (%CV C12hr (nM)
Slovenian: geometrijska sredina (% KV C12ur (nM)
English: See section 4.4 regarding the need to administer raltegravir with two other active agents.
Slovenian: Glede potrebe po uporabi raltegravirja skupaj z dvema drugima učinkovinama glejte poglavje 4.4.
English: Renal impairment No dosage adjustment is required for patients with renal impairment (see section 5.2).
Slovenian: Okvara ledvic Pri bolnikih z okvaro ledvic odmerka ni treba prilagajati (glejte poglavje 5.2).
English: No data are available in pre-term neonates.
Slovenian: Podatkov za nedonošene novorojenčke ni na voljo.
English: Excipient with known effect Each 600 mg tablet contains 5.72 mg lactose (as monohydrate).
Slovenian: Pomožna snov z znanim učinkom Ena 600 mg tableta vsebuje 5,72 mg laktoze (v obliki monohidrata).
English: Treatment-experienced adult patients
Slovenian: Predhodno že zdravljeni odrasli bolniki
English: Week 48 and Week 96 outcomes from ONCEMRK are shown in Table 4.
Slovenian: Izidi študije ONCEMRK v 48. tednu in 96. tednu so prikazani v preglednici 4.
English: In vitro studies indicate that raltegravir is not a substrate of cytochrome P450 (CYP) enzymes, does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A, does not inhibit UDP glucuronosyltransferases (UGTs) 1A1 and 2B7, does not induce CYP3A4 and is not an inhibitor of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion-transporting polypeptides (OATP) 1B1, OATP1B3, organic cation transporters (OCT)1 and OCT2, or multidrug and toxin extrusion proteins (MATE)1 and MATE2-K. Based on these data, raltegravir is not expected to affect the pharmacokinetics of medicinal products that are substrates of these enzymes or transporters.
Slovenian: In vitro študije kažejo, da raltegravir ni substrat za encime citokroma P450 (CYP), ne zavira CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 ali CYP3A, ne zavira UDP glukuronoziltransferaz (UGT) 1A1 in 2B7, ne inducira CYP3A4 in ni zaviralec P-glikoproteina (P-gp), proteina odpornosti pri raku dojke (BCRP - breast cancer resistance protein), polipeptidov za prenos organskih anionov (OATP - organic anion-transporting polypeptides) OATP1B1, OATP1B3, prenašalcev organskih kationov (OCT - organic cation transporters) OCT1 in OCT2 ali proteinov za ekstruzijo več zdravil in toksinov (MATE - multidrug and toxin extrusion proteins) MATE1 in MATE2-K. Na osnovi teh podatkov se ne pričakuje, da bi raltegravir vplival na farmakokinetiko zdravil, ki so substrati za te encime ali prenašalce.
English: Based on these data, proton pump inhibitors and H2 blockers may be co-administered with raltegravir 1,200 mg once daily.
Slovenian: Na osnovi teh podatkov se zaviralci protonske črpalke in antagonisti histaminskih receptorjev H2 lahko uporabljajo sočasno s 1.200 mg raltegravirja enkrat na dan.
English: Uncommon: the following may affect up to 1 in 100 people
Slovenian: Občasni: pojavijo se lahko pri največ 1 od 100 bolnikov
English: Results 48-week and 96-week analyses
Slovenian: Rezultati 48-tedenske in 96-tedenske analize
English: emtricitabine and tenofovir disoproxil fumarate (raltegravir 1,200 mg (2 x 600 mg) Once Daily)
Slovenian: emtricitabin in tenofovirdizoproksil fumarat (raltegravir 1.200 mg (2 x 600 mg) enkrat na dan)
English: Snap the lid of the mixing cup shut.
Slovenian: Pokrovček posodice za mešanje zaprite.
English: STARTMRK Study
Slovenian: študija STARTMRK
English: Each single-use sachet contains 100 mg of raltegravir which is to be suspended in 10 mL of water giving a final concentration of 10 mg per mL (see section 6.6).
Slovenian: Eno vrečico za enkratno uporabo, ki vsebuje 100 mg raltegravirja, je treba suspendirati v 10 ml vode, da nastane suspenzija s končno koncentracijo 10 mg/ml (glejte poglavje 6.6).
English: Raltegravir was administered with an optimised background regimen.
Slovenian: Raltegravir so prejemali poleg optimiziranega osnovnega režima zdravljenja.
English: tenofovir AUC  10% tenofovir C24hr  13% tenofovir Cmax ↓ 23%
Slovenian: tenofovir AUC  10 % tenofovir C24ur  13 % tenofovir Cmax ↓ 23 %
English: Raltegravir chewable tablets should be used during pregnancy only if the expected benefit justifies the potential risk to the foetus.
Slovenian: Raltegravir žvečljive tablete se lahko med nosečnostjo uporablja samo, če pričakovana korist upravičuje morebitno tveganje za plod.
English: Co-administration of raltegravir with medicinal products that are known to be potent UGT1A1 inhibitors (e.g., atazanavir) may increase plasma levels of raltegravir.
Slovenian: Pri sočasni uporabi raltegravirja in zdravil, ki so znani močni zaviralci UGT1A1 (npr. atazanavir), se lahko povečajo plazemske koncentracije raltegravirja.
English: • Isentress granules for oral suspension are not recommended in pregnancy because they have not been studied in pregnant women.
Slovenian: • Uporaba zdravila Isentress zrnca za peroralno suspenzijo med nosečnostjo ni priporočljiva, saj uporabe tega zdravila pri nosečnicah niso raziskovali.
English: High density polyethylene (HDPE) bottle with a child-resistant polypropylene closure, induction seal and silica gel desiccant: 60 tablets.
Slovenian: Plastenke iz polietilena visoke gostote (HDPE) z za otroke varno polipropilensko zaporko, z indukcijskim tesnilom in sušilnim sredstvom iz silikagela: 60 tablet.
English: Caution is recommended when co-administering raltegravir 1,200 mg once daily with sensitive OAT1 and/or OAT3 substrates.
Slovenian: Pri sočasni uporabi raltegravirja 1.200 mg enkrat na dan z občutljivimi substrati OAT1 in/ali OAT3 je potrebna previdnost.
English: The treatment difference (raltegravir 1,200 mg once daily-raltegravir 400 mg twice daily) was 1.5 % with an associated 95 % CI of (-4.4, 7.3).
Slovenian: Razlika med zdravljenjem (1.200 mg raltegravirja enkrat na dan in 400 mg raltegravirja dvakrat na dan) je bila 1,5 % in s 95 % IZ (-4,4, 7,3).
English: In general, the safety profile of raltegravir in patients with hepatitis B and/or hepatitis C virus co-infection was similar to that in patients without hepatitis B and/or hepatitis C virus co-infection, although the rates of AST and ALT abnormalities were somewhat higher in the subgroup co-infected with hepatitis B and/or hepatitis C virus.
Slovenian: Pri bolnikih s sočasno okužbo z virusom hepatitisa B in/ali virusom hepatitisa C je bil varnostni profil raltegravirja na splošno podoben kot pri bolnikih brez sočasne okužbe z virusom hepatitisa B in/ali virusom hepatitisa C, čeprav so bili deleži nenormalnih vrednosti AST in ALT nekoliko večji v podskupini, ki je bila sočasno okužena z virusom hepatitisa B in/ali virusom hepatitisa C.
English: ISENTRESS should be used in combination with other active anti-retroviral therapies (ARTs) (see sections 4.4 and 5.1).
Slovenian: Zdravilo ISENTRESS je treba uporabljati v kombinaciji z drugimi protiretrovirusnimi zdravili (glejte poglavji 4.4 in 5.1).
English: Bring this booklet to your child's appointments.
Slovenian: Knjižico prinesite s seboj na vsak otrokov pregled.
English: No dose adjustment required for raltegravir or tenofovir disoproxil fumarate.
Slovenian: Odmerka raltegravirja ali tenofovirdizoproksil fumarata ni treba prilagajati.
English: The Genotypic Sensitivity Score (GSS) was defined as the total oral ARTs in the optimised background therapy (OBT) to which a patient's viral isolate showed genotypic sensitivity based upon genotypic resistance test. Enfuvirtide use in OBT in enfuvirtide-naïve patients was counted as one active drug in OBT.
Slovenian: Rezultat genotipske občutljivosti (GSS; “Genotypic Sensitivity Score”) je definiran kot skupno število peroralnih protiretrovirusnih zdravil pri optimiziranem osnovnem zdravljenju na katera so bili izolati virusa pri testiranju genotipske odpornosti genotipsko občutljivi.
English: From the clinical trials, a large proportion of patients used atazanavir and / or tenofovir disoproxil fumarate, both agents that result in increases in raltegravir plasma levels, in the optimised background regimens.
Slovenian: V kliničnih preskušanjih je velik delež bolnikov v sklopu optimiziranega osnovnega zdravljenja (OBT - optimized background therapy) uporabljal atazanavir in/ali tenofovirdizoproksil fumarat, zdravili, ki povečata plazemske koncentracije raltegravirja.
English: Talk with your doctor about the best way to feed your baby.
Slovenian: O najprimernejši obliki prehrane otroka se posvetujte z zdravnikom.
English: Patient demographics (gender, age and race) and baseline characteristics were comparable between the group receiving raltegravir 400 mg twice daily and the group receiving efavirenz 600 mg at bedtime.
Slovenian: Demografske (spol, starost in rasa) in izhodiščne značilnosti bolnikov so bile med skupino, ki je prejemala raltegravir v odmerku 400 mg dvakrat na dan, in skupino, ki je prejemala efavirenz v odmerku 600 mg pred spanjem, primerljive.
English: Uncommon alanine aminotransferase increased, atypical lymphocytes, aspartate aminotransferase increased, blood triglycerides increased, lipase increased, blood pancreatic amylase increased absolute neutrophil count decreased, alkaline phosphatase increased, blood albumin decreased, blood amylase increased, blood bilirubin increased, blood cholesterol increased, blood creatinine increased, blood glucose increased, blood urea nitrogen increased, creatine phosphokinase increased, fasting blood glucose increased, glucose urine present, high density lipoprotein increased, international normalised ratio increased, low density lipoprotein increased, platelet count decreased, red blood cells urine positive, waist circumference increased, weight increased, white blood cell count decreased
Slovenian: Preiskave pogosti zvišana alanin-aminotransferaza, atipični limfociti, zvišana aspartat-aminotransferaza, zvišani trigliceridi v krvi, zvišana lipaza, zvišana pankreatična amilaza v krvi občasni zmanjšano absolutno število nevtrofilcev, zvišana alkalna fosfataza, znižani albumini v krvi, zvišana amilaza v krvi, zvišan bilirubin v krvi, zvišan holesterol v krvi, zvišan kreatinin v krvi, zvišana glukoza v krvi, zvišana sečnina v krvi, zvišana kreatin fosfokinaza, zvišana glukoza v krvi na tešče, prisotnost glukoze v urinu, zvišani lipoproteini velike gostote (HDL), povišano internacionalno normalizirano razmerje, zvišani lipoproteini majhne gostote (LDL), zmanjšano število trombocitov, pozitiven izvid eritrocitov v urinu, povečan obseg pasu, povečanje telesne mase, zmanjšano število belih krvnih celic
English: If co-administration with rifampicin is unavoidable, a doubling of the dose of raltegravir (400 mg twice daily) can be considered.
Slovenian: Če je sočasna uporaba rifampicina nujna, je treba razmisliti o podvojitvi odmerka raltegravirja (400 mg dvakrat na dan).
English: † 10 mL (100 mg) twice daily 1 x 100 mg twice daily 20 to less than 25
Slovenian: † 10 ml (100 mg) dvakrat na dan 1 x 100 mg dvakrat na dan od 20 do manj kot 25